@article{ac30d237875947a7bacb338b363b44a8,
title = "Small Molecule SARM1 Inhibitors Recapitulate the SARM1−/− Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate",
abstract = "Axonal degeneration is prevalent in neurodegenerative disorders of the central and peripheral nervous systems. Hughes et al. developed potent small molecule inhibitors of SARM1, a central driver of axonal degeneration, that protect axons and allow recovery of already-injured axons that otherwise would degenerate. SARM1 inhibition may treat axonal degeneration.",
keywords = "ALS, CIPN, SARM1, Wallerian, WldS, axonal degeneration, axonopathy, multiple sclerosis, neurodegeneration, neuropathy",
author = "Hughes, {Robert O.} and Todd Bosanac and Xianrong Mao and Engber, {Thomas M.} and Aaron DiAntonio and Jeffrey Milbrandt and Rajesh Devraj and Raul Krauss",
note = "Funding Information: We thank Ken Young, Markus Ketelhot, Niels Banek, and Antoine Berthemy for their expertise in cell culture and metabolite analysis and members of Disarm Therapeutics for helpful comments and advice during the preparation of this manuscript. This study was funded by Disarm Therapeutics. Funding Information: We thank Ken Young, Markus Ketelhot, Niels Banek, and Antoine Berthemy for their expertise in cell culture and metabolite analysis and members of Disarm Therapeutics for helpful comments and advice during the preparation of this manuscript. This study was funded by Disarm Therapeutics. R.K. and R.O.H. jointly conceived the study. R.K. supervised the project, designed experiments, interpreted and analyzed data, and wrote the manuscript. R.O.H. and T.B. designed and supervised experiments and analyzed data leading to identification and development of small molecule chemical matter. X.M. A.D. and J.M. designed the SAM-TIR NADase assay, R.O.H. T.M.E. T.B. R.D. A.D. and J.M. edited the manuscript and contributed to interpretation of the data. R.O.H. T.B. T.M.E. R.D. and R.K. are employees and shareholders of Disarm Therapeutics, a wholly owned subsidiary of Eli Lilly & Co. R.O.H. T.B. T.M.E. R.D. R.K. A.D. X.M. and J.M. are inventors on patents related to this work. A.D. and J.M. are cofounders and shareholders of Disarm Therapeutics and members of its scientific advisory board. The authors have no other competing conflicts or financial interests. Publisher Copyright: {\textcopyright} 2020 The Author(s)",
year = "2021",
month = jan,
day = "5",
doi = "10.1016/j.celrep.2020.108588",
language = "English",
volume = "34",
journal = "Cell Reports",
issn = "2211-1247",
number = "1",
}